S42 The Genetic Era in Osteoporosis Treatment

Program: Symposia
Clinical/Translational Session
Saturday, April 2, 2016: 4:45 PM-6:15 PM
Room 253 (BCEC)
Chair:
Robert A Nissenson, MD, VA Medical Center/University of California-San Francisco, San Francisco, CA

Nothing to Disclose: RAN
4:45 PM
Robert L Jilka, PhD, Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, University of Arkansas for Medical Sciences/Central Arkansas Veterans Healthcare System, Little Rock, AR
Nothing to Disclose: RLJ
5:15 PM
Edward C. Hsiao, MD, PhD, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California-San Francisco, San Francisco, CA
Disclosures:
ECH: Clinical Researcher, Clementia Pharmaceuticals.
5:45 PM
Jane B Lian, PhD, Biochemistry, University of Vermont College of Medicine, Burlington, VT
Nothing to Disclose: JBL
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire